Kyverna Therapeutics, Inc. announced that it has received a round of funding on January 13, 2020. The transaction included participation from returning investors Vida Ventures, Westlake Village BioPartners and new investor Gilead Sciences, Inc. As part of the transaction, Beth Seidenberg and Desmond Padhi of Westlake Village BioPartners and one additional representative of Vida Ventures will serve on the company's the board of directors. Fred Cohen of Vida Ventures will serve as chairman of the board.

On the same date company received $25 million in its first tranche.